Course Outline
Technologies for drug discovery are constantly evolving. Significant developments within the last 20 years range from the development of DNA-encoded libraries for hit finding and even hit-to-lead optimisation to the reinvigoration of irreversible inhibitors resulting in innovative oncology drugs such as osimertinib and sotorasib.
This course will cover advanced methods, new technologies and tools available for medicinal chemists, with a focus on oncology drug discovery, including fragment based-drug discovery, DNA-encoded library technologies, covalent drug discovery and small molecules that target RNA. The course will finish with a series of oncology case studies successfully utilising these drug discovery technologies for the development of clinical candidates and marketed drugs.
Course Set-up
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to 3 applicants from academia may be admitted at a reduced fee.
Technologies for drug discovery are constantly evolving. Significant developments within the last 20 years range from the development of DNA-encoded libraries for hit finding and even hit-to-lead optimisation to the reinvigoration of irreversible inhibitors resulting in innovative oncology drugs such as osimertinib and sotorasib.
This course will cover advanced methods, new technologies and tools available for medicinal chemists, with a focus on oncology drug discovery, including fragment based-drug discovery, DNA-encoded library technologies, covalent drug discovery and small molecules that target RNA. The course will finish with a series of oncology case studies successfully utilising these drug discovery technologies for the development of clinical candidates and marketed drugs.
Course Set-up
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to 3 applicants from academia may be admitted at a reduced fee.
